Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

CointegrationX Jun. 11 at 3:15 PM

$JNJ remains focused on healthcare innovation, pharmaceuticals, and medical technologies. RMTG reported strong demand for regenerative medicine training and clinic support services.

0 · Reply

Trader_Ty Jun. 11 at 2:41 PM

$JNJ Will add on a dip for the bull flag breakout trade

0 · Reply

Estimize Jun. 11 at 2:12 PM

Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont

0 · Reply

Diefreeandsell Jun. 11 at 12:34 PM

$IBRX $XBI $MRK $JNJ $TNA Once cross over minor res @7.15 next res is easy to get to next level that takes it over $7.5. Self reinforcing loop by MM's . KNicks pulled it off, so will IBRX!!!

0 · Reply

ElliottwaveForecast Jun. 11 at 9:07 AM

$JNJ Buyers from #Bluebox area looking for rally targeting above 259.3 or higher It was expected double correction to finish in #Bluebox between 227.8 - 215.82 area for next rally within January-2025 rally. It ended as anticipated and reacting higher now. #Elliottwave #JNJ

0 · Reply

mikesterz7 Jun. 11 at 6:55 AM

$JNJ 🚨🚨🚨 Johnson & Johnson reported pivotal Phase 2/3 ENERGY data for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, a disease with no FDA-approved therapies. The 30 mg/kg group achieved statistically significant durable hemoglobin response and about three times more responders than placebo by 24 weeks. Mean hemoglobin rose ≥1 g/dL by Week 1, nearly two-thirds met stringent hemoglobin targets by Week 24, fatigue and corticosteroid use improved, safety matched the existing profile, and the sBLA has FDA Priority Review.

0 · Reply

mikesterz7 Jun. 11 at 6:54 AM

$JNJ wow

0 · Reply

focafoca99 Jun. 11 at 6:10 AM

$JNJ demonstrated durable hemoglobin response in Phase 2/3 ENERGY trial for IMAAVY in wAIHA. https://www.rapidticker.com/news/jnj-imaavy-nipocalimab-aahu-demonstrates-durable-0327bd

0 · Reply

Suite510 Jun. 11 at 2:46 AM

$JNJ $KVUE $SPX oh darn it, more news 🗞️ J&J Talc Claimants Win OK For UK Group Asbestos Suit By Joanne Faulkner June 10, 2026, 12:19 PM BST Thousands of women were granted permission on Wednesday to join together in litigation accusing Johnson & Johnson of knowingly selling baby powder in the U.K. that was contaminated with asbestos....

2 · Reply

Suite510 Jun. 11 at 1:38 AM

$JNJ $SPX $KVUE Whoops 😬 another Big “L” J&J Hit With $32M Verdict In LA Baby Powder Cancer TrialA Los Angeles jury Tuesday awarded $32 million to the family of a woman who died of mesothelioma and who said she used Johnson's Baby Powder on herself and her children for decades, finding the product was a substantial factor in causing her illness.

0 · Reply

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Jun 11, 2026, 7:45 AM EDT - 3 hours ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 4 hours ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

2026-06-11T09:26:54.000Z - 5 hours ago

Johnson & Johnson presents first results from ENERGY study

Jun 11, 2026, 2:03 AM EDT - 9 hours ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 1 day ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 1 day ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 2 days ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 2 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 3 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

2026-06-08T13:00:56.000Z - 3 days ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T12:14:56.000Z - 3 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash

Jun 8, 2026, 8:08 AM EDT - 3 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 3 days ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 5 days ago

J&J beats lawsuit alleging that talc caused three women's cancer

2026-06-03T09:38:11.000Z - 8 days ago

Johnson & Johnson presents exploratory analyses from DAHLIAS study

2026-06-03T09:31:04.000Z - 8 days ago

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

Jun 3, 2026, 12:04 AM EDT - 8 days ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 8 days ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 8 days ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

2026-05-31T21:41:49.000Z - 10 days ago

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

2026-05-31T21:40:07.000Z - 10 days ago

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

May 31, 2026, 8:39 AM EDT - 11 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 11 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 11 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 11 days ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 12 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

2026-05-29T12:49:22.000Z - 13 days ago

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

May 29, 2026, 8:18 AM EDT - 13 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 13 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 14 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 14 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 15 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 21 days ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 21 days ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 22 days ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 23 days ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 27 days ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 4 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 4 weeks ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 5 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 5 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 5 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 5 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 5 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 6 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 6 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 6 weeks ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 6 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 6 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 6 weeks ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 23, 2026, 10:00 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: AGM 2026

Apr 22, 2026, 8:05 AM EDT - 7 weeks ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 7 weeks ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 17, 2026, 10:36 PM EDT - 7 weeks ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 7 weeks ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

CointegrationX Jun. 11 at 3:15 PM

$JNJ remains focused on healthcare innovation, pharmaceuticals, and medical technologies. RMTG reported strong demand for regenerative medicine training and clinic support services.

0 · Reply

Trader_Ty Jun. 11 at 2:41 PM

$JNJ Will add on a dip for the bull flag breakout trade

0 · Reply

Estimize Jun. 11 at 2:12 PM

Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont

0 · Reply

Diefreeandsell Jun. 11 at 12:34 PM

$IBRX $XBI $MRK $JNJ $TNA Once cross over minor res @7.15 next res is easy to get to next level that takes it over $7.5. Self reinforcing loop by MM's . KNicks pulled it off, so will IBRX!!!

0 · Reply

ElliottwaveForecast Jun. 11 at 9:07 AM

0 · Reply

mikesterz7 Jun. 11 at 6:55 AM

0 · Reply

mikesterz7 Jun. 11 at 6:54 AM

$JNJ wow

0 · Reply

focafoca99 Jun. 11 at 6:10 AM

$JNJ demonstrated durable hemoglobin response in Phase 2/3 ENERGY trial for IMAAVY in wAIHA. https://www.rapidticker.com/news/jnj-imaavy-nipocalimab-aahu-demonstrates-durable-0327bd

0 · Reply

Suite510 Jun. 11 at 2:46 AM

2 · Reply

Suite510 Jun. 11 at 1:38 AM

0 · Reply

Sak12345 Jun. 11 at 12:18 AM

$JNJ defichain.com Can you trade a token that tracks the Goldman Sachs stock price — without a brokerage account, without KYC, and without waiting for Wall Street’s trading hours? That’s the specific thing DeFiChain built. When DeFiChain announced the addition of four new dTokens — dJNJ (Johnson & Johnson), dDAX (DAX ETF), dADS (Adidas), and dGS (Goldman Sachs) — it was adding to a system already offering tokenized versions of Tesla, Apple, Amazon, Google, and dozens of other traditional financial assets. All of it running on a blockchain built as a fork of Bitcoin, anchored to the Bitcoin network every few minutes for security. JNJ

0 · Reply

Wallstfan Jun. 10 at 7:30 PM

$AMZN Geeze I mine as sell and just buy $JNJ LOL. This thing could drop to that $205- 213 range soon

0 · Reply

Trader_Ty Jun. 10 at 4:23 PM

$JNJ bull flag breakout here

0 · Reply

option4kingjesus Jun. 10 at 4:12 PM

$JNJ are we bullish due to earings run up? follow for more info.

0 · Reply

focafoca99 Jun. 10 at 3:40 PM

$JNJ suffered a $32 million verdict in a Los Angeles asbestos trial. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-hit-with-6de303

1 · Reply

VeltrixCapitalOfficial Jun. 10 at 2:31 PM

SUPER HIGH CONFIDENCE 🚨 6/12 $JNJ 250c @.22 1000 CONTRACTS

1 · Reply

GTNew Jun. 10 at 2:21 PM

$JNJ Trend line breakout

0 · Reply

flgoldpanther Jun. 10 at 2:19 PM

$JNJ How is this not trending ?

0 · Reply

Woodman7 Jun. 10 at 1:15 PM

$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news

0 · Reply

Quantumup Jun. 10 at 11:26 AM

BofA⬆️ $TYRA's PT to $42 (was $37), reiterated Buy and said: After a strong start to 2026, sentiment on Tyra has cooled despite seemingly little change to the story (since May: TYRA -25% vs. NBI flat). CGON URGN $JNJ ENGN IBRX $TARA Here's what BofA went on to say: https://x.com/Quantumup1/status/2064669900359016705?s=20

0 · Reply

TW_Research Jun. 10 at 11:01 AM

This is really a breast cancer story right now. GBM may end up getting some great news from the FDA but that's not why you should be investing in $KZIA . The base case scenario is we kick ass in TNBC, add on other breast indications, and start working our way towards a valuation like $CELC has. Upside from GBM would be wonderful but we'll still be worth billions without Jon Friend ever mentioning it again. BTW, did you see $JNJ bought Firefly Bio for $1B in CASH?! They have a preclinical degrader. Kazia has two of those programs. We are early innings here people...lots of runway in front of us. @futureexmillionare @ocellated

1 · Reply

cwEWF Jun. 10 at 9:52 AM

$JNJ favors rally to 259 or higher in daily from #bluebox area It is showing only 3 swing bounce from 5.11.2026 low and extend towards 236 - 245.4 area before pullback starts against 6.01.2026 low. Check before/after forecasts. #Elliottwave #JNJ

0 · Reply

Market Cap	570.51B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.64
Forward PE	20.07
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	8,350,700
Avg Vol	7,638,458
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	88%
Beta	0.26
Analysts	Strong Sell
Price Target	$260.46